Articles

ST.26 vs ST.25: Understanding the Key Differences for Patent Filers

If you are involved in patent filing, especially for biotechnology or pharmaceutical inventions, you have likely heard about the shift from ST.25 to ST.26. This change is one of the most significant updates in the world of intellectual property documentation in recent years. Understanding the st.26 st.25 comparison is no longer optional for patent professionals. It is a necessity. Whether you are a patent attorney, a bioinformatics specialist, or a first-time inventor filing a sequence listing, this article will walk you through everything you need to know in plain, simple language.

What is ST.25 and Why Was It Used?

ST.25 is the older WIPO (World Intellectual Property Organization) standard used to disclose nucleotide and amino acid sequences in patent applications. It was introduced in the 1990s and served the patent community for decades. Under this standard, sequence listings were submitted as plain text files with a specific format defined by WIPO’s recommendations.

The ST.25 format used a flat text structure, which worked well in its time. However, as biology and genomics evolved rapidly, the limitations of this format became more apparent. The files were difficult to validate automatically, data exchange between patent offices was inconsistent, and integration with modern biological databases was clunky and error-prone.

What is ST.26 and Why Was It Introduced?

ST.26 is the new WIPO standard for sequence listings that officially replaced ST.25 on July 1, 2022. It is based on XML (Extensible Markup Language), which is a universally recognized data format used widely in technology, healthcare, and scientific data exchange.

The primary goal of ST.26 was to modernize the way biological sequences are disclosed in patents. XML allows for structured, machine-readable data, which means automated validation, better interoperability between international patent offices, and more accurate representation of complex biological information.

This st.26 st.25 comparison is not just about format. It reflects a broader shift in how the global patent system handles scientific data.

ST.26 vs ST.25: The Core Differences Explained

This is where most filers get confused. Let us break down the differences clearly.

1. File Format

The most obvious difference in any st.26 st.25 comparison is the file format itself.

ST.25 used plain text (.txt) files with numeric codes and a rigid but simple layout.
ST.26 uses XML (.xml) files that follow a specific schema defined by WIPO.

XML files are larger in size but far more structured. They carry metadata, validation rules, and annotations that plain text simply cannot support.

2. Scope of Coverage

ST.25 covered nucleotide and amino acid sequences only. ST.26 expanded the scope significantly. It now also covers:

Linear and circular sequences
Sequences with non-standard residues and modified bases
Sequences with gaps or unknown regions using standardized notation
D-amino acids and other unusual biological entities

This broader scope makes st.26 more aligned with modern genomics and synthetic biology.

3. Language and Annotations

Under ST.25, annotations were limited and often inconsistent. ST.26 introduces standardized feature annotations using controlled vocabulary from databases like the Feature Table Documentation used by INSDC (International Nucleotide Sequence Database Collaboration). This means every sequence can carry rich biological context in a consistent, searchable format.

Key Practical Differences Every Patent Filer Must Know

Here is where the st.26 st.25 comparison becomes most relevant for day-to-day patent work. Understanding these points will save you time, money, and rejection headaches.

Tool Requirement: To create ST.26-compliant files, you must use WIPO’s free tool called WIPO Sequence. There is no longer an option to manually create a text file as was common with ST.25.
Validation is Built-In: The WIPO Sequence tool validates your file before submission, reducing the risk of errors being flagged by patent offices after filing.
No More Backward Compatibility: Applications filed on or after July 1, 2022 must use ST.26. You cannot submit an ST.25 file for a new application. However, applications filed before that date that already have an ST.25 sequence listing are generally not required to convert.
Priority Applications: If you are filing a PCT application and your priority application was filed before July 1, 2022 with an ST.25 sequence listing, you may need to provide a new ST.26-compliant listing for the international phase. Always verify with the receiving office.
Numbering Changes: In ST.25, sequence identifiers started from 1. In ST.26, sequences are also numbered from 1, but the XML structure handles identifiers differently. This can cause confusion when cross-referencing claims and descriptions, so extra care is needed during drafting.
File Size and Submission Portals: Because XML files can be larger, some patent offices have updated their submission portals. Always confirm the file size limits with the target patent office before submitting.

Common Mistakes Filers Make During the Transition

Even experienced patent professionals have stumbled during the st.26 st.25 comparison and transition period. Here are the most common pitfalls:

Using outdated software: Some firms continued using old ST.25 generation tools out of habit. Always use the latest version of WIPO Sequence for new filings.

Incorrect organism names: ST.26 requires organism names to follow specific taxonomic conventions. Informal or abbreviated names that were acceptable in ST.25 may cause validation errors in ST.26.

Mixing old and new standards: Some applicants mistakenly attach an ST.25 text file alongside a description written for ST.26. This creates inconsistency and can be grounds for an office action.

Not updating internal templates: Law firms and IP departments often use internal templates for sequence disclosures. These templates must be updated to reflect ST.26 requirements in both format and language.

Why This Transition Matters Beyond Compliance

The st.26 st.25 comparison goes beyond administrative compliance. It has real implications for the quality and enforceability of your patent.

A well-formatted ST.26 sequence listing improves the clarity of your disclosure. It makes it easier for patent examiners to understand and search your sequences. It also reduces the risk of your sequences being missed or misinterpreted during examination, which can affect the breadth and strength of your claims.

Furthermore, as global databases increasingly rely on XML-based data exchange, having your sequences disclosed in ST.26 format ensures they are compatible with future search tools and patent analytics platforms. This future-proofs your intellectual property.

Final Thoughts

The shift from ST.25 to ST.26 is a positive step forward for the global patent system, even if the learning curve feels steep at first. By understanding the st.26 st.25 comparison in depth, patent filers can avoid costly errors, ensure compliance across multiple jurisdictions, and ultimately protect their inventions more effectively.

If you are new to ST.26, start by downloading and exploring the WIPO Sequence tool. Familiarize yourself with the XML structure and run test files before your actual submission. And if you are managing a portfolio of existing ST.25 filings, consult with your patent office or agent about whether and when conversion may be required.

Staying informed is the best strategy in a constantly evolving IP landscape.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.